Bridging Innovation for Health

Integrated, end-to-end solutions across the pharmaceutical value chain, spanning customized API and intermediate sourcing, pipeline licensing, and international product registration

APIs and Intermediates Licensing

United, We Can Be the Best!

Partners

Projects

Audits

Years Experience

Why Choose Us

01 / 06

One-Stop Solution

Unified Access: Your single gateway to a full spectrum of assets, from APIs and intermediates to strategic licensing

Explore All

02 / 06

Products Varieties

Products range from finished drugs (Rx/OTC), APIs, Intermediates, Excipients, to even licensing opportunities for clinical-stage novel drugs

Explore All

03 / 06

Global Business Centers

Our strategically located business centers across key continents form a powerful, integrated network

Explore All

04 / 06

International Registration Experience

The team has participated in the completion of 16 NDA/BLA and more than 100 IND applications for new drugs

Explore All

05 / 06

Digital Intelligence Platform

AI-powered analytics for market forecasting, candidate valuation, and risk assessment

Explore All

06 / 06

Culture Alignment

Our team members come from different countries with different cultural backgrounds

Explore All

News

industry2026.08.10

FDA Approves Moderna's mflusiva as First mRNA Flu Vaccine, Opening Major New Manufacturing Demand for Lipid Nanoparticle CDMOs

The FDA has cleared Moderna's mflusiva as the first mRNA-based seasonal influenza vaccine, validating the platform beyond COVID-19 and creating billions in new manufacturing demand for lipid nanoparticle CDMOs, plasmid DNA suppliers, and mRNA fill-finish specialists.

industry2026.08.10

Intellia Identifies HLA Genetic Risk Factor for Liver Toxicity in CRISPR Trial, Paving the Way for Safer Gene Editing Manufacturing and Patient Stratification

Intellia Therapeutics has identified HLA allele C*05:01 as a key risk factor for liver enzyme elevations in its CRISPR ATTR amyloidosis trial, transforming an open safety question into a manageable biomarker and strengthening the commercial case for liver-targeted gene editing manufacturing.

industry2026.08.07

Replimune's Tudriqev Wins FDA Approval for Melanoma After Two Rejections, Validating Oncolytic Virus Manufacturing and Opening New Biologics Demand

The FDA grants accelerated approval to Replimune's oncolytic virus immunotherapy Tudriqev for advanced melanoma following two prior rejections and a contentious advisory committee vote, validating oncolytic virus manufacturing platforms and creating new demand for specialized viral vector production infrastructure.

industry2026.08.07

LifeMine Raises $263M to Advance First-in-Class Fungal-Derived Immunosuppressant, Signaling New Manufacturing Paradigm for Transplant Medicine

LifeMine Therapeutics secures $263 million in Series D and E funding to advance LIFE-001, a fungal genome-derived calcineurin inhibitor designed to replace decades-old tacrolimus and cyclosporine in organ transplant patients, creating demand for specialized fermentation-based API manufacturing capabilities.

View All News

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here